Bruce A. Feinberg, DO: Hope, where do you think this all shakes out in 5 years? Are biosimilars really well entrenched in our armamentarium of therapeutics? People are using them as they use generics today, to Marcus’s point. Is there a biosimilar for this? Does that happen? Where do you think we are?
Hope S. Rugo, MD: I think that we’re going to see an incorporation of biosimilars into the market. I think that originator product manufacturers, producers, are going to try different ways of making their product different—either by packaging or giving it a different way. That will allow them to have the main part of the market share, such as we’ve seen with pegfilgrastim, which is something that really benefits patients, I will say, for several different reasons. And the alternative drugs, of course, will be out there. They are not yet ready to be off patent and be biosimilars, however.
I think biosimilars are going to be part of our daily life in prescribing. We’re going to be able to use biosimilars. I think, in the United States, we are not going to be able to choose which one we give. We’re going to be able to comment on it. And if somebody has a reaction to one and not the other, which we haven’t seen yet in any of the trials, we would be able to make a case—a peer-to-peer, etc—like we do now. But otherwise, I think they’re just going to be incorporated into our practices, and we’re not going to have a big choice as to which one is going to be incorporated into our particular practice or into, for example, a purchasing group in the group practices that are out there.
In the rest of the world, we’ve already seen the incorporation of biosimilars in the European market, and they seem to be well tolerated. I haven’t heard of any significant concerns there. They’ve been way ahead of us in the biosimilar area because they have had shorter patent lives and, also, because of the cost structure with the way things are covered. Biosimilar therapeutic agents are already being incorporated into treatment planning in other parts of the world. I was talking to a colleague from the United Arab Emirates, where biosimilars are coming and will be used in the very near future once they’re approved because of cost savings for the governments in that situation. So, I think that we will join in in this general area despite our different payment structures, and biosimilars will become part of what we use.
Bruce A. Feinberg, DO: Dr. Rugo, Dr. Snow, and Dr. Shank, it has been my pleasure to get to work with you today on the panel. Thank you all for your contributions to this discussion. On behalf of our panel, we thank you for joining us and we hope you found this Peer Exchange• discussion to be useful and informative.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.